검색
Novo Nordisk A/S
NVO관심 목록에 추가
37.185USD
-0.135-0.36%
시장 운영 시간 10/05, 12:55（ET）
164.32B시가총액
8.70P/E TTM
Novo Nordisk A/S 정보 회사
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Novo Nordisk A/S 프로필
종목 코드 NVO
회사 이름Novo Nordisk A/S
상장일May 17, 1974
CEODoustdar (Maziar Mike)
직원 수76302
유형Depository Receipt
회계 연도 종료May 17
주소Novo Alle 1
도시BAGSVAERD
증권 거래소NASDAQ OMX NASDAQ Basic NYSE
국가Denmark
우편 번호2880
전화4544448888
웹사이트https://www.novonordisk.com/
종목 코드 NVO
상장일May 17, 1974
CEODoustdar (Maziar Mike)
Novo Nordisk A/S의 회사 임원진
이름
이름/직위
직위
주식 보유
변동
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Thomas Rantzau
Mr. Thomas Rantzau
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Ludovic Helfgott
Mr. Ludovic Helfgott
Executive Vice President - Product and Portfolio Strategy
Executive Vice President - Product and Portfolio Strategy
--
--
Dr. Martin Holst Lange
Dr. Martin Holst Lange
Executive Vice President, Chief Scientific Officer, Research and Development
Executive Vice President, Chief Scientific Officer, Research and Development
--
--
더 보기
이름
이름/직위
직위
주식 보유
변동
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Ms. Liselotte Hyveled
Ms. Liselotte Hyveled
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Henrik Ehlers Wulff
Mr. Henrik Ehlers Wulff
Executive Vice President - Product Supply
Executive Vice President - Product Supply
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
자주 묻는 질문
Novo Nordisk A/S의 상위 5대 주주는 누구인가요?
Novo Nordisk A/S의 상위 5대 주주는 다음과 같습니다: Mr. Lars Rebien Soerensen
Novo Nordisk A/S(NVO)의 주식을 보유한 기관은 몇 개입니까?
2026Q1 기준으로, Novo Nordisk A/S의 주식을 보유한 기관은 총 2975곳이며, 이들이 보유한 주식의 총 가치는 약 332.82M로 전체 발행 주식의 9.89%를 차지합니다. 이는 2025Q4 대비 -2714627.00 증가한 수치입니다.
Novo Nordisk A/S의 최대 수익원은 무엇인가요?
2026Q1 기준, Novo Nordisk A/S의 Total GLP-1 부문이 가장 높은 매출을 기록했으며, 금액은 5.72B로 전체 매출의 46.87%를 차지했습니다.